Soluble VCAM-1 (sVCAM-1 / CD106)
Transmembrane sialoglycoprotein shed into plasma from endothelial cells specifically in regions predisposed to early atherosclerotic lesion formation.
Standard vs. Optimal Reference Rangesng/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
350 - 800 ng/mL
General reference distribution across unselected commercial populations.
<500 ng/mL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds alpha-4-beta-1 integrin (VLA-4) on monocytes and T-lymphocytes, mediating selective monocyte recruitment into fatty streaks.
Differential Diagnosis
Elevated Levels (sVCAM-1 / CD106 High)
- •Early-stage atherosclerotic lesion formation and fatty streaks
- •Diabetic microvascular and macrovascular disease
- •Chronic kidney disease vasculopathy
Low Levels (sVCAM-1 / CD106 Low)
- •Healthy, quiescent vascular intima (<500 ng/mL)
- •Absence of active subendothelial monocyte recruitment
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for sVCAM-1 / CD106
- Targeted organ system imaging or functional dynamic testing related to monocyte rolling & early atherogenesis
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Soluble VCAM-1 - The New England Journal of Medicine (2021). PMID: 34190124
- [2]sVCAM-1 / CD106 Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Soluble VCAM-1 (sVCAM-1 / CD106) into overall healthspan optimization.